Galuia, M., Mchayleh, J. G., Karakozis, L., Abdelmasseh, M., Nassif, G., Soliman, M., Albert, M., Kelly, J., Tejani, M. A., Zakari, A. (2026). Minimal residual disease (MRD) assessment by circulating tumor DNA (ctDNA) to stratify recurrence risk and adjuvant treatment benefit in a real-world colorectal cancer (CRC) cohort.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3616